Alasdhair McDonald

Alasdhair has significant experience in conducting patent litigation and dispute resolution in the pharmaceutical and technology sectors and advising on life sciences regulatory matters. He regularly provides strategic patent advice and acts on validity and infringement actions in the High Court. He has also acted on two of the largest patent cross-undertaking damages claims in the English Courts.

Alasdhair has in-house experience with the Global IP Litigation team of a major pharmaceutical company. He holds a degree in biological sciences and the Oxford University Diploma in IP Law and Practice.

Year joined firm: 2021

• Acted for Sandoz and Accord, successfully invalidating Bayer's patent concerning rivaroxaban ([2024] EWHC 796 (Pat), [2024] EWCA Civ 562), and for Sandoz in the follow on damages inquiry
• Acted for Sandoz in litigation against Astellas concerning mirabegron, successfully defending a claim for infringement of a formulation patent ([2022] EWHC 1316 (Pat), [2023] EWCA Civ 880, [2023] EWHC 2571 (Pat))
• Acted for Sandoz for Sandoz in infringement and  follow-on damages proceedings concerning each of pregabalin and buprenorphine, with the damages inquiries being two of the largest ever seen in the English Patents Court
• Acted for Boston Scientific in a patent invalidity action and infringement action regarding transcatheter heart valves, [2017] EWHC 405 (Pat)

• Biology BSc, Manchester University, 2008